1. Home
  2. RAND vs XLO Comparison

RAND vs XLO Comparison

Compare RAND & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RAND
  • XLO
  • Stock Information
  • Founded
  • RAND 1969
  • XLO 2016
  • Country
  • RAND United States
  • XLO United States
  • Employees
  • RAND N/A
  • XLO N/A
  • Industry
  • RAND Finance: Consumer Services
  • XLO Biotechnology: Pharmaceutical Preparations
  • Sector
  • RAND Finance
  • XLO Health Care
  • Exchange
  • RAND Nasdaq
  • XLO Nasdaq
  • Market Cap
  • RAND 44.7M
  • XLO 40.9M
  • IPO Year
  • RAND N/A
  • XLO 2021
  • Fundamental
  • Price
  • RAND $13.51
  • XLO $0.79
  • Analyst Decision
  • RAND
  • XLO Buy
  • Analyst Count
  • RAND 0
  • XLO 2
  • Target Price
  • RAND N/A
  • XLO $3.00
  • AVG Volume (30 Days)
  • RAND 3.4K
  • XLO 475.7K
  • Earning Date
  • RAND 11-07-2025
  • XLO 11-07-2025
  • Dividend Yield
  • RAND 12.37%
  • XLO N/A
  • EPS Growth
  • RAND N/A
  • XLO N/A
  • EPS
  • RAND N/A
  • XLO N/A
  • Revenue
  • RAND $7,966,118.00
  • XLO $15,001,000.00
  • Revenue This Year
  • RAND N/A
  • XLO $519.70
  • Revenue Next Year
  • RAND N/A
  • XLO $44.57
  • P/E Ratio
  • RAND N/A
  • XLO N/A
  • Revenue Growth
  • RAND 1.16
  • XLO 536.45
  • 52 Week Low
  • RAND $13.50
  • XLO $0.62
  • 52 Week High
  • RAND $31.89
  • XLO $1.70
  • Technical
  • Relative Strength Index (RSI)
  • RAND 38.17
  • XLO 53.98
  • Support Level
  • RAND $13.55
  • XLO $0.73
  • Resistance Level
  • RAND $14.49
  • XLO $0.85
  • Average True Range (ATR)
  • RAND 0.43
  • XLO 0.05
  • MACD
  • RAND -0.03
  • XLO -0.00
  • Stochastic Oscillator
  • RAND 0.00
  • XLO 43.25

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Share on Social Networks: